Séverine Lambot

Dr. Séverine Lambot

CRCINA UMR1232
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LLLisa Lindesmith
Lisa Lindesmith
CMChristine Moe
Christine Moe
SLSéverine Lambot
Séverine Lambot
NRNathalie Ruvoen
Nathalie Ruvoen
XJXi Jiang
Xi Jiang
RBRalph Baric
Ralph Baric

1 June 2002 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SLSéverine Lambot
Séverine Lambot
NRNathalie Ruvoën
Nathalie Ruvoën
BMBeatrice Le Moullac–Vaidye
Beatrice Le Moullac–Vaidye
MCMonique Clement
Monique Clement
ACAnne Cailleau–Thomas
Anne Cailleau–Thomas
JPJacques Le Pendu
Jacques Le Pendu

1 July 2003 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
PHPengwei Huang
Pengwei Huang
TFTibor Farkas
Tibor Farkas
SLSéverine Lambot
Séverine Lambot
WZWeiming Zhong
Weiming Zhong
NRNathalie Ruvoën‐Clouet
Nathalie Ruvoën‐Clouet
XJXi Jiang
Xi Jiang
We characterized the binding of 8 Noroviruses (NORs) to histo-blood group antigens (HBGAs) in human saliva using recombinant NOR (rNOR) capsid protei

1 July 2001 in Biochimie
Verified
Journal Article
Closed access
SLSéverine Lambot
Séverine Lambot
ACAnne Cailleau-Thomas
Anne Cailleau-Thomas
JRJézabel Rocher
Jézabel Rocher
BMBéatrice Le Moullac-Vaidye
Béatrice Le Moullac-Vaidye
NRNathalie Ruvoën
Nathalie Ruvoën
JPJacques Le Pendu
Jacques Le Pendu

1 January 2001 in APMIS
Verified
Journal Article
Closed access
PDF file
JPJacques LE Pendu
Jacques LE Pendu
SLSéverine Lambot
Séverine Lambot
ACAnne Cailleau‐Thomas
Anne Cailleau‐Thomas
JRJézabel Rocher
Jézabel Rocher
BMBéatrice LE Moullac‐Vaidye
Béatrice LE Moullac‐Vaidye
MCMonique Clément
Monique Clément

31 July 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ACAurélie Chantôme
Aurélie Chantôme
MPMarie Potier-Cartereau
Marie Potier-Cartereau
LCLucie Clarysse
Lucie Clarysse
GFGaëlle Fromont
Gaëlle Fromont
SLSéverine Lambot
Séverine Lambot
CVChristophe Vandier
Christophe Vandier
The SK3 channel, a potassium channel, was recently shown to control cancer cell migration, a critical step in metastasis outgrowth. Here, we report that expression of the SK3 channel was markedly associated with bone metastasis. The SK3 channel was shown to control constitutive Ca2+ entry and cancer cell migration through an interaction with the Ca2+ channel Orai1. We found that the SK3 channel triggers an association with the Orai1 channel within lipid rafts. This localization of an SK3–Orai1 complex seemed essential to control cancer cell migration. This suggests that the formation of this complex in lipid rafts is a gain-of-function, because we showed that none of the individual proteins were able to promote the complete phenotype. We identified the alkyl-lipid Ohmline as a disrupting agent for SK3–Orai1 lipid raft localization. Upon Ohmline treatment, the SK3–Orai1 complex moved away from lipid rafts, and SK3-dependent Ca2+ entry, migration, and bone metastases were subsequently impaired. The colocalization of SK3 and Orai1 in primary human tumors and bone metastases further emphasized the clinical relevance of our observations. Targeting SK3–Orai1 in lipid rafts may inaugurate innovative approaches to inhibit bone metastases. Cancer Res; 73(15); 4852–61. ©2013 AACR.